Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMDSR1X)

Drug Name
PD-157695 Drug Info
Cross-matching ID
PubChem CID
3854666
ChEBI ID
CHEMBL93074
CAS Number
CAS 182498-32-4
TTD Drug ID
D0F6WV

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Focal adhesion 2.17 0.00e+0 180/201 (89.55%) ITGA6;ACTN1;CAPN2;...
Malaria 1.96 5.97e-3 44/50 (88%) THBS1;CXCL8;SDC2;...
Rap1 signaling pathway 1.92 1.19e-2 184/210 (87.62%) THBS1;RALA;PRKCA;...
Arrhythmogenic right ventricular cardiomyopathy 1.92 8.95e-3 70/77 (90.91%) ITGA6;GJA1;ITGA3;...
Dilated cardiomyopathy 1.91 7.16e-3 86/96 (89.58%) ITGA6;TPM1;TPM4;...
Intestinal immune network for IgA production 1.90 5.97e-3 38/48 (79.17%) CD86;TGFB1;IL15RA;...
ErbB signaling pathway 1.88 6.82e-3 79/85 (92.94%) HBEGF;PRKCA;CRK;...
Hypertrophic cardiomyopathy 1.86 8.95e-3 81/90 (90%) ITGA6;TPM1;TPM4;...
Tuberculosis 1.86 9.28e-3 159/180 (88.33%) CD14;CALML5;FCER1G;...
ECM-receptor interaction 1.83 9.55e-3 80/88 (90.91%) ITGA6;THBS1;CD44;...
Glycosaminoglycan biosynthesis 1.81 1.08e-2 40/58 (68.97%) CSGALNACT1;CHST1;CHST15;...
Fc gamma R-mediated phagocytosis 1.80 1.09e-2 79/97 (81.44%) PRKCA;CRK;FCGR2A;...
African trypanosomiasis 1.80 1.01e-2 32/37 (86.49%) PRKCA;IDO1;PLCB3;...
Salmonella infection 1.80 1.02e-2 198/249 (79.52%) PODXL;KIF5B;CXCL8;...
Melanogenesis 1.80 9.55e-3 74/101 (73.27%) PRKCA;CALML5;DVL1;...
Amoebiasis 1.79 8.95e-3 99/102 (97.06%) ACTN1;CXCL8;ACTN4;...
Hippo signaling pathway 1.79 8.42e-3 120/186 (64.52%) BIRC5;DVL1;DCHS1;...
Hematopoietic cell lineage 1.79 7.96e-3 90/99 (90.91%) ITGA6;IL4R;IL7R;...
Yersinia infection 1.79 7.54e-3 120/137 (87.59%) CXCL8;CRK;FCGR2A;...
VEGF signaling pathway 1.79 7.16e-3 50/59 (84.75%) MAPKAPK2;PRKCA;AKT1;...
Regulation of actin cytoskeleton 1.78 6.82e-3 185/218 (84.86%) ITGA6;ACTN1;ACTN4;...
Phospholipase D signaling pathway 1.77 7.05e-3 134/148 (90.54%) CXCL8;RALA;PRKCA;...
Asthma 1.77 6.74e-3 25/31 (80.65%) FCER1G;HLA-DOB;HLA-DMB;...
Proteoglycans in cancer 1.76 7.46e-3 172/205 (83.9%) PLAUR;THBS1;HBEGF;...
Oxytocin signaling pathway 1.75 9.07e-3 128/154 (83.12%) PRKCA;CALML5;RGS2;...
Toxoplasmosis 1.74 1.15e-2 103/112 (91.96%) ITGA6;AKT1;LAMC2;...
Progesterone-mediated oocyte maturation 1.73 1.46e-2 75/100 (75%) PLK1;AURKA;CCNB2;...
Proteasome 1.70 1.83e-2 44/46 (95.65%) PSMD9;PSMB7;PSMA2;...
Fc epsilon RI signaling pathway 1.69 1.79e-2 57/68 (83.82%) PRKCA;FCER1G;ALOX5AP;...
Viral protein interaction with cytokine and cytokine re... 1.69 1.81e-2 84/100 (84%) CXCL8;TNFRSF1B;CCR2;...
Ribosome -1.58 3.76e-2 113/158 (71.52%) RPL18;MRPL17;RPLP2;...
Histidine metabolism -1.60 3.45e-2 16/22 (72.73%) ASPA;MAOB;ALDH9A1;...
Collecting duct acid secretion -1.60 3.54e-2 22/27 (81.48%) ATP6V1G1;ATP6V0E2;ATP6V1A;...
Tryptophan metabolism -1.62 2.94e-2 35/42 (83.33%) CAT;DLD;ALDH8A1;...
Valine, leucine and isoleucine degradation -1.62 3.02e-2 42/48 (87.5%) BCKDHA;HMGCL;MCCC1;...
Folate biosynthesis -1.63 2.72e-2 23/26 (88.46%) QDPR;ALPG;GPHN;...
Homologous recombination -1.63 2.77e-2 35/41 (85.37%) TOP3A;BARD1;TOP3B;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.64 2.55e-2 20/26 (76.92%) PIGV;PGAP1;PIGH;...
Fatty acid elongation -1.65 2.67e-2 19/27 (70.37%) ELOVL6;ELOVL2;HACD2;...
Galactose metabolism -1.66 2.47e-2 26/31 (83.87%) LCT;GLA;SI;...
Retinol metabolism -1.69 1.91e-2 41/68 (60.29%) ADH6;CYP2C9;UGT2B4;...
Non-homologous end-joining -1.70 1.85e-2 11/13 (84.62%) PRKDC;MRE11;POLM;...
Nucleotide excision repair -1.72 1.61e-2 40/47 (85.11%) POLD1;DDB1;GTF2H1;...
Primary bile acid biosynthesis -1.72 1.53e-2 15/17 (88.24%) CYP7B1;CH25H;CYP7A1;...
Tyrosine metabolism -1.74 1.48e-2 30/36 (83.33%) TPO;GSTZ1;ADH6;...
Nitrogen metabolism -1.75 1.27e-2 16/17 (94.12%) GLUD1;CA3;GLUD2;...
Glycolysis / Gluconeogenesis -1.76 1.36e-2 56/67 (83.58%) ADH6;PFKL;ENO2;...
Fanconi anemia pathway -1.84 4.70e-3 36/54 (66.67%) RPA2;BRCA1;BLM;...
Pyruvate metabolism -1.85 5.09e-3 41/47 (87.23%) ME2;ADH6;DLD;...
Terpenoid backbone biosynthesis -1.90 2.77e-3 18/22 (81.82%) FNTB;MVD;GGPS1;...
Drug metabolism -1.93 2.29e-3 78/151 (51.66%) GUSB;GSTP1;FMO4;...
Steroid hormone biosynthesis -1.94 2.54e-3 43/61 (70.49%) UGT2B4;AKR1C4;CYP3A4;...
One carbon pool by folate -1.96 9.54e-4 15/20 (75%) MTHFD2L;TYMS;DHFR;...
Glycine, serine and threonine metabolism -1.98 1.09e-3 31/40 (77.5%) ALAS1;DLD;GAMT;...
Glyoxylate and dicarboxylate metabolism -2.07 0.00e+0 23/30 (76.67%) CAT;DLD;ACO2;...
Pentose and glucuronate interconversions -2.07 0.00e+0 17/34 (50%) GUSB;DCXR;SORD;...
Metabolism of xenobiotics by cytochrome P450 -2.09 0.00e+0 49/77 (63.64%) ADH6;CYP2C9;UGT2B4;...
Mismatch repair -2.20 0.00e+0 22/23 (95.65%) POLD2;RFC1;RPA2;...
DNA replication -2.27 0.00e+0 34/36 (94.44%) RPA2;POLD4;MCM7;...
Steroid biosynthesis -2.36 0.00e+0 19/20 (95%) CYP51A1;TM7SF2;HSD17B7;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 12uM 6H
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.37uM - 12uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 12uM 6H
HT-29 CVCL_0320 Homo sapiens 10uM - 12uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 12uM 6H
MDST8 CVCL_1400 Homo sapiens 12uM 6H
NCI-H508 CVCL_1561 Homo sapiens 12uM 6H
SNU-1040 CVCL_5001 Homo sapiens 12uM 6H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
SNU-C4 CVCL_5008 Homo sapiens 12uM 6H
SNU-C5 CVCL_5009 Homo sapiens 12uM 6H
SW480 CVCL_0546 Homo sapiens 12uM 6H
SW620 CVCL_0547 Homo sapiens 12uM 6H
SW948 CVCL_0550 Homo sapiens 12uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 12uM 6H
HT115 CVCL_1294 Homo sapiens 12uM 6H
RKO CVCL_0504 Homo sapiens 12uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 12uM 6H, 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
SNG-M CVCL_1707 Homo sapiens 12uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 12uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM - 12uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM - 12uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM - 12uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 12uM 6H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
SK-LU-1 CVCL_0624 Homo sapiens 12uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 12uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 12uM 6H
T3M-10 CVCL_1729 Homo sapiens 12uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC15 CVCL_1253 Homo sapiens 12uM 6H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 12uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM - 12uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 12uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 12uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 12uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 12uM 6H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 12uM 6H
OV7 CVCL_1623 Homo sapiens 12uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
RMG-I CVCL_1663 Homo sapiens 12uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 12uM 6H
RMUG-S CVCL_1666 Homo sapiens 12uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 12uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 12uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 12uM 6H
PL-21 CVCL_2161 Homo sapiens 12uM 6H
SKM-1 CVCL_0010 Homo sapiens 12uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 12uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM - 12uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM - 12uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM - 12uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
SK-MEL-1 CVCL_0523 Homo sapiens 12uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 12uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 12uM 6H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H